New York State Common Retirement Fund boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 13.5% in the fourth quarter, Holdings Channel reports. The fund owned ...

Opthea Limited Sponsored ADR ( ($OPT) ) has released its Q2 earnings. Here is a breakdown of the information Opthea Limited Sponsored ADR ...

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has ...

Liver cancer in the Philippines holds a staggering mortality rate of 11.6 out of 100,000 individuals, compared to the global death rate of 7.8/100,000. This reflects the significant impact of liver ...

A Chinese woman made the unconventional decision to leave her lucrative job to pursue her passion for animals, becoming a ...

A notable NIH reform rolled out by Trump was a $4 billion cut to overhead funding for biomedical research by reducing ...

Dasgupta left India in 1985 and moved to the US to pursue an undergraduate degree that allowed her to major in biochemistry ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

1. Characterization of lipid components in lipid nanoparticle (LNP) formulations – Application Note AN001928 – an-001928-bt-lipid-components-LNP-an001928-na-en.pdf (SECURED) ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...